AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01116986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive phone counseling during the quit attempt
Description: Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
Study NCT00003193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate
Study NCT00003193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00003193 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00905138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: single ascending doses, oral solution
Study NCT00905138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution
Study NCT00905138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: multiple dose, oral solution, 5 days
Study NCT00905138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral solution, 5 days
Study NCT03314597 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise
Description: Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
Study NCT03314597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile platform exercise
Description: Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
Study NCT02422056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
Study NCT02422056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of saline in the same rate used for the intervention group
Study NCT02158520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02158520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02158520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02158520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT02158520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01653184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
Study NCT02719678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General health checks
Description: The intervention group is invited to up to three general health checks over a 10-year period
Study NCT01659619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: 125mg in normal saline single use infusion for 5 min.
Study NCT03497754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probefix
Description: A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
Study NCT00969878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-CD Vaccination
Description: On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
Study NCT00969878 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
Study NCT01266733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment
Description: The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
Study NCT01266733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment of fibromyalgia
Description: The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
Study NCT02673424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR-guided stenting
Description: The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~\* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI
Study NCT02673424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS-guided stenting
Description: The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~\* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden >70%)
Study NCT04481477 — intervention group
Intervention type: OTHER
Intervention: Nursing care to reduce anxiety, fear and loneliness
Description: Decreased anxiety Presence Emotional support Improved security Increasing coping capacity Presence Emotional support Facilitating visits
Study NCT01749605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days
Study NCT01749605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin 250 mg BID x 3 days
Study NCT00421200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemospan (MP4OX)
Description: 250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
Study NCT00421200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voluven (HES 130/0.4)
Description: 250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
Study NCT04107350 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: whole-body vibration
Description: 10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
Study NCT04107350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration
Description: 10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
Study NCT01707225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR Depot
Description: The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
Study NCT00247377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass surgery
Description: in order to meet health requirements for patient, gastric bypass surgery was undergone
Study NCT00247377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap-Band
Description: in order to meet health requirements for patient, gastric band surgery was undergone
Study NCT02573220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT02573220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02573220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02573220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT05430893 — intervention group
Intervention type: OTHER
Intervention: Botulinum Toxin A
Description: 100 UI IM in the adductor longus
Study NCT00992433 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza H1N1 vaccine
Description: Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
Study NCT03800641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: oral, intravenous and nasal administration of Dexmedetomidine
Study NCT03800641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: oral, intravenous and nasal administration of Dexmedetomidine
Study NCT01313637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 125/25mcg
Description: 125/25mcg
Study NCT01313637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 125mcg
Description: 125mcg
Study NCT01313637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25mcg
Description: 25mcg
Study NCT01313637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo only
Description: Placebo
Study NCT03177278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-plazomicin
Description: single intravenous dose
Study NCT03126708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
Study NCT03126708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin plus paclitaxel
Description: Chemotherapy
Study NCT03126708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin plus paclitaxel
Description: Chemotherapy
Study NCT00221169 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical resection
Description: pet ct prior to surgery
Study NCT03354806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous peripheral nerve blocks
Description: 6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
Study NCT03354806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic treatment
Description: 6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
Study NCT01589666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 100 mL Spray-dried S/D-treated Plasma
Study NCT01589666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated plasma
Description: Infusion of 200mL Spray-dried S/D-treated plasma
Study NCT01589666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 500 mL Spray-dried S/D-treated plasma
Study NCT01589666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 750 mL Spray-dried S/D-treated Plasma
Study NCT01589666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spray-dried S/D-treated Plasma
Description: Infusion of 800 mL Spray-dried S/D-treated Plasma
Study NCT02229045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Bound Paclitaxel
Description: Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
Study NCT02229045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
Study NCT04152460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Viscalor Bulk (VOCO,Cuxhaven)
Description: Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
Study NCT04152460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grandioso x-tra
Description: Nanohybrid Bulk Resin Composite
Study NCT03575754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Ultrasound Gastrostomy
Description: A balloon catheter is inserted into the stomach and used to appose tissue between anterior stomach and skin. Fluid fills the balloon, enabling ultrasound visualization. Then a guidewire is inserted, and pulled out through the mouth to create wire-to-wire (through and through) access. At that point, a gastrostomy tube is placed over it using over-the-wire (push) technique.
Study NCT00502021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manioc powder (placebo) 60 g/day
Study NCT00502021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid/ALA
Description: Flaxseed powder 60 g/day (10 g ALA)
Study NCT00502021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha linolenic acid/ALA
Description: Flaxseed oil 30 ml/day (10 g ALA)
Study NCT00502021 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Safflower oil 30 ml/day
Study NCT00744523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mo.Ma cerebral protection device
Description: Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
Study NCT02904486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: change behavior
Description: Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
Study NCT00484731 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Infiltration with Saline
Description: Infiltration with Bupivacaine according to protocol
Study NCT00484731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration with Bupivacaine
Study NCT04528927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: 600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days
Study NCT04528927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500 mg (1st day) then 250 mg / D for 4 days
Study NCT04528927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200 mg per day for 10 days
Study NCT04528927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 220 mg per day for 10 days
Study NCT04312321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandatory phone call consultation
Description: Use of audio consultation (EMS crew smartphones, doctor smarphone) Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk)
Study NCT04312321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandatory audiovisual consultation
Description: Smartphone (Xiaomi Redmi Note) and bluetooth handsfree headset (Jabra Talk) with installed Android application (VSee messenger, USA, HIPAA compliant software) for paramedic crews; personal computer (Windows 10) with desktop version of application VSee messenger for Windows and eqipped with webcamera (Logitech C922 PRO) and headset (Jabra Evolve 20) for consulting doctor.
Study NCT03054480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Micro-Needle Radiofrequency
Study NCT03054480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Study NCT00629330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
Study NCT02149082 — intervention group
Intervention type: DEVICE
Intervention: Infrascanner Model 2000
Description: The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
Study NCT02261597 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cold Pressor Test
Description: Repeated immersion of hand in ice-cold water
Study NCT03422354 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided PVB with General Aneasthesia
Description: An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min
Study NCT03422354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound
Study NCT03422354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral block
Description: Patients will receive single shot L1-L2 PVB before undergoing GA